
BCYC Stock Forecast & Price Target
BCYC Analyst Ratings
Bulls say
Bicycle Therapeutics is a biopharmaceutical company with a strong focus on oncology and a promising product, zele, in its pipeline. The company has a current cash position that makes it well-equipped to fund its operations and continue advancing in clinical trials for zele. In addition, with potential partnerships and collaborations in the works, the company's BRC platform could hold valuable potential for future growth.
Bears say
Bicycle Therapeutics is facing challenges with its product development as evidenced by the discontinuation of two clinical trials and the decision to seek a potential partner for future development. Despite having a strong cash position as of YE25, the company has proposed a workforce reduction of approximately 30%, which may signify internal struggles. In addition, the company's competitive positioning may be weakened by potential superior efficacy and safety profiles of next-generation Nectin-4 ADCs with enhanced payloads. These challenges could limit the company's market share and pricing power and may result in dilution or alterations to its financing structures.
This aggregate rating is based on analysts' research of Bicycle Therapeutics Plc - ADR and is not a guaranteed prediction by Public.com or investment advice.
BCYC Analyst Forecast & Price Prediction
Start investing in BCYC
Order type
Buy in
Order amount
Est. shares
0 shares